Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: A tertiary referral center experience

American Journal of Gastroenterology

Volumn 100, Issue 5, 2005, Pages 1121-1125

  Bajaj, Jasmohan S ^a   Saeian, Kia ^b   Varma, Rajiv R ^b   Franco, Jose ^b   Knox, Joshua F ^b   Podoll, Judy ^b   Emmons, Jeanne ^b   Levy, Michael ^b   Binion, David G ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; PREDNISONE; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT;

ACUTE PANCREATITIS; ADULT; AGED; ARTHRALGIA; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG WITHDRAWAL; ENTERITIS; FEMALE; FEVER; FISHER EXACT TEST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; REVIEW; STATISTICAL SIGNIFICANCE; VOMITING; ACUTE DISEASE; ARTICLE; CHEMICALLY INDUCED DISORDER; DISEASE PREDISPOSITION; MIDDLE AGED; PANCREATITIS;

ACUTE DISEASE; ADULT; ANTI-INFLAMMATORY AGENTS; ARTHRALGIA; AZATHIOPRINE; CROHN DISEASE; DISEASE SUSCEPTIBILITY; DRUG HYPERSENSITIVITY; EXANTHEMA; FEMALE; FEVER; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NAUSEA; PANCREATITIS; PREDNISONE; RETROSPECTIVE STUDIES; VOMITING;

EID: 19144372392     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.41598.x     Document Type: Review

References (31)

1. Sandborn W, Sutherland L, Pearson DC, et al. Azathioprine for inducing remission of Crohn's disease. Cochrane Database System Review, 2001, CD000067.
2. Czaja A. Drug therapy in the management of type 1 autoimmune hepatitis. Drugs 1999;57(1):49-68.
3. Navarro F, Hanauer S. Treatment of inflammatory bowel disease: Safety and tolerability issues. Am J Gastroenterol 2003;98:S18-S23.
4. Lamers CBHW, Griffioen G, van Hogezand RA, et al. Azathioprine: An update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol 1999;(suppl 230):111-5.
5. Kirschner B. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998;115:813-21.
6. Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004;14(3):181-7.
7. Schroder O, Stein J. Low dose methotrexate in inflammatory bowel disease: Current status and future directions. Am J Gastroenterol 2003;98(3):530-7.
8. de Jong DJ, Goullet M, Naber THJ. Side effects of azathioprine in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2004:16(2):207-12.
9. Loftus CG, Loftus EV, Tremaine WJ, et al. The safety profile of azathioprine/6 mercaptopurine in the treatment of inflammatory bowel disease: A population-based study in Olmsted County, Minnesota. Am J Gastroenterol 2003;98(9):S242.
10. Medina J, Garcia-Buey L, Moreno-Otero R. Immunopathogenetic and therapeutic aspects of autoimmune hepatitis, Aliment Pharmacol Ther 2003;17:1-16.
11. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002;35:7-13.
12. Balthazar EJ, Robinson DL, Megibow AJ, et al. Acute pancreatitis: Value of CT in establishing prognosis. Radiology 1990;174:331.
13. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8(4):244-50.
14. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37(5):674-8.
15. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: A 30-year review. Gut 2002;50(4):485-9.
16. Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359(9317):1541-9.
17. Feagan BG, Fedorak RN, Irvine EJ, et al. North American Crohn's Study Group Investigators. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med 2000;342(22):1627-32.
18. Dubinsky MC, Feldman EJ, Abreu MT, et al. Thioguanine: A potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol 2003;98(5):1058-63.
19. Prajapati DN, Knox JF, Emmons J, et al. Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy. J Clin Gastroenterol 2003;37(2):125-8.
20. Weinshelboum RM, Sladek SI. Mercaptopurine pharmacogenetics. Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32: 651-62.
21. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine S methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 18(4):395-400.
22. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118(6):1025-30.
23. Langley PG, Underhill J, Tredger JM, et al. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 2002;37(4):441-7.
24. Haverkos HW, Amsel Z, Drotman DP. Adverse virus-drug interactions. Rev Infect Dis 1991;13(4):697-704.
25. Pope J, Jerome D, Fenlon D, et al. Frequency of adverse drug reactions in patients with systemic lupus erythematosus. J Rheumatol 2003;30(3):480-4.
26. Kounev V, Attila T, Saeian K, et al. Increased rates of drug allergies in inflammatory bowel disease patients as compared to irritable bowel disease patients and normal controls. Gastroenterology 2003;124:A214.
27. Feagan BG. Maintenance therapy for inflammatory bowel disease. Am J Gastroenterol 2003;98:S6-S17.
28. Cuffari C, Hunt S, Bayless T. Utilization of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with inflammatory bowel disease. Gut 2001;48:642-6.
29. Loftus EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126(6):1504-17.
30. Jacobson D, Gange S, Rose N, et al. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997;84(3):223-43.
31. Dubinsky MC. 6-thioguanine can cause serious liver injury in inflammatory bowel disease. Gastroenterology 2003;125(2):298-303.